Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like it's holding up above the downtrend line. Let's get a reversal going!
Looking into the recent Vivo 13G/A (Rule 13d-1(c)) filing, I came across this website that had an interesting deadline fact. I actually was looking at all of Vivo's filings for the same day they filed for BioPharmX and was wondering why they had so many on the same day.
Here is the paragraph on the website I found interesting.
"Are you a large investment fund with dozens - or hundreds - of Schedule 13Gs to file by the February 14th deadline?"
I was unaware of this Feb. 14th deadline and thought it would be interesting to share.
Here is the website with that info. Link
Here's Vivo's filings for that deadline date. BioPharmX is in that lineup. Link
Still very interested in the details of the recent filing with BioPharmX and look forward to their update!
Looks like interest is gaining!
You too!
I usually don't mess with these low low price ones anymore. Had my "got burned days" with some real winners like FITX and MTVX in the past, but I decided to take a gamble and throw a small amount here. Lotto play I guess.
GLTY as well!
Well that would suck wouldn't it. Eh, let's see how it plays out. I'm a gambling man on this one so I wouldn't spend too much time trying to change my mind, but I'm here for you if you need the conversation.
Appears that way huh, lol. I didn't throw much at it, so I'm in for the hold to better days!
Looking good!
Time for this one to wake up! Great news out!
Right! We need to hear something from the company!
Vivo Increase
Largest institutional holder of biopharmx increased their position!
https://www.sec.gov/Archives/edgar/data/1504167/000161577419002506/s116130_sc13ga.htm
Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the fourth quarter ended December 31, 2018, on Thursday, February 28, after the markets close. Foamix will host a conference call and webcast at 8:30 a.m. Eastern Time on Friday, March 1.
Conference Call & Webcast Friday, March 1st @ 8:30am Eastern Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13687390 Webcast: http://public.viavid.com/index.php?id=133210 Replays, Available through March 15th: Toll-Free: 844-512-2921 Internation al: 412-317-6671 Conference ID: 13687390 A replay will also be archived on the Company's website at www.foamix.com promptly after the conference call.
Form S3 Notice of Effectiveness
Company has been quiet about upcoming 27th compliance rule deadline. I'm thinking extension news here soon! As mentioned in my previous post, AKER received a second extension. 27th closing in!
Broke below the 3 month pennant. If .10's don't hold, .09's are the next stop.
It has to fall below $0.06 to get delisted and the company would enact the RS before that happens.
We are going to see movement this week or the beginning of next week for sure. There is a tight pennant wedge forming on the 3 month chart. It will either break up or down as it reaches the point of the wedge. From a chart perspective, the move will send out an alert to day trader's and we will see a rush of volume here real soon.
Question is, who will win the battle? Bulls or Bears?
Ruff draft example
Feb. 27th Compliance Deadline.
Most likely BPMX will be granted an extension as AKER's did last year.
https://globenewswire.com/news-release/2018/05/30/1514342/0/en/Akers-Biosciences-Granted-180-Day-Extension-by-Nasdaq-to-Meet-Minimum-Bid-Price-Requirement.html
Dr. R. Todd Plott from the panel to the board. CEO Tierney starting to line things up!
https://www.prnewswire.com/news-releases/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology-300667178.html
BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott
Dr. R. Todd Plott, developer of SOLODYN™, ZIANA™, and NORITATE™, becomes company's third independent director
SAN JOSE, Calif., Feb. 4, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced the appointment of veteran pharmaceutical developer R. Todd Plott, M.D., as an independent director.
Dr. Plott is a board-certified dermatologist with 30 years of experience; 16 years of which were spent working as a research physician with the pharmaceutical industry. He has been involved in nine prescription drug development programs that received approvals from the U.S. Food and Drug Administration and other agencies. He personally led and supervised five of these programs from initiation through approval. Dr. Plott has built and led the development and regulatory teams that have produced some of the most successful products in medical dermatology including, but not limited to, SOLODYN™, an extended-release minocycline HCl tablet for the treatment of inflammatory lesions of acne vulgaris, ZIANA™, a clindamycin phosphate and tretinoin combination gel for the treatment of acne vulgaris, VANOS™, a fluocinonide cream for the treatment of psoriasis, and NORITATE™, a metronidazole cream for the treatment of rosacea.
Dr. Plott served as Vice President, Clinical Research and Regulatory Affairs and later Consulting Dermatologist at Medicis Pharmaceutical Company, a specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions from 2001 through 2007. Prior to Medicis, Dr. Plott served as a Director in Clinical Research at leading pharmaceutical companies with emphasis in dermatology including Schering-Plough, Galderma Laboratories and Dermik Laboratories. As a result of his extensive experience, he was appointed to the FDA Dermatologic and Ophthalmic Drug Advisory Committee. During his distinguished career, Dr. Plott has monitored tens of thousands of patients and hundreds of clinical trials. Dr. Plott returned to private practice in 2011, where he currently serves as Chief Medical Officer for Epiphany Dermatology based in Austin, Texas.
"Dr. Plott's impressive experience will be invaluable to BioPharmX as we progress through clinical research on our path to FDA approval," said Dr. David Tierney, BioPharmX CEO. "His deep knowledge of the development and regulatory process will provide insight that will help BioPharmX remain focused on our goal of offering dermatologists and their patients new treatment options. We are thrilled that he is joining our team."
"I am honored to join the BioPharmX board of directors, which shares my passion for developing needed dermatology products," said Dr. Plott. "BioPharmX is working on two investigational products that may someday deliver efficacy and safety benefits over existing therapeutic options. I look forward to contributing my expertise to the BioPharmX team as we work together to improve patient outcomes."
With an impressive $152MM portfolio value, I would consider this investor valid. Apparently they like what they see in BioPharmX by upping there stake by 2/3.
https://fintel.io/i/empery-asset-management-lp
"SEC review, and the time it takes to receive SEC clearance following the filing of a Form S-3 is relatively short (often, 10 days or less), this gap period between the public filing of a Form S-3 and its subsequent effectiveness is generally suboptimal for companies that want to move quickly and opportunistically to raise capital."
I'm still digesting the news...
Good to see. Appreciate the update.
Right! lol... It always sucks being on this side of our investment, but it's only temporary (imo). Dr. T will succeed!
Circuit breaker halt. Moving up again! Almost 50% now.
I like the fact that they have multiple things in the works!
David Jin Interview
Ok nice. I hope you get another little run up then!
How's your order? Did you keep it there or move it?
David Jin spoke this morning, although I wasn't expecting any movement from that.
Hopefully you were able to capitalize a bit on that one.
Good call. I don't think it has the strength for another push.
I was thinking about jumping in on that dip into the 6's but just got stuck watching, lol
Yep, after yesterday's run, no surprise today.
Right now AVCO is the day trader's playground. Can you guys run it up some more for more profit fun? Is there anything left after a 130% run tho?
I've actually been thinking this run up is to prepare for a public offering. We'll know the answer in time.
Yeah, that's scary territory there
I'm out now. I added a bit more to my portfolio tho. Nice day!
Wow, what a run! This thing was paused like five times today due to the volatility.
Nevermind, blew past that!!
Wow, almost at 100% gain on the day!
Yep! Excellent volume today definitely makes this a fun one!